126 related articles for article (PubMed ID: 17100315)
1. [Technology of immunoglobulin production. I. Technological aspects of purification].
Volkov GL
Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
[TBL] [Abstract][Full Text] [Related]
2. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
Buchacher A; Iberer G
Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
[TBL] [Abstract][Full Text] [Related]
3. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
Radosevich M; Burnouf T
Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulins and their use in children.
Łaguna P; Gołębiowska-Staroszczyk S; Trzaska M; Grabarczyk M; Matysiak M
Adv Clin Exp Med; 2015; 24(1):153-9. PubMed ID: 25923100
[TBL] [Abstract][Full Text] [Related]
6. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.
Miller JL; Petteway SR; Lee DC
J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S91-4. PubMed ID: 11586272
[TBL] [Abstract][Full Text] [Related]
7. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
8. Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM
Wasserman RL; Garcia D; Greener BN; Kestenberg K; Pinkert A; Mond J; Grossman A
Immunotherapy; 2019 Nov; 11(16):1423-1433. PubMed ID: 31596642
[TBL] [Abstract][Full Text] [Related]
9. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases.
Blank M; Bashi T; Shoenfeld Y
Methods Mol Biol; 2014; 1060():353-61. PubMed ID: 24037850
[TBL] [Abstract][Full Text] [Related]
10. HPLC fingerprinting approach for raw material assessment and unit operation tracking for IVIG production from Cohn I+II+III fraction.
Peljhan S; Jakop T; Šček D; Skvarča V; Goričar B; Žabar R; Mencin N
Electrophoresis; 2017 Nov; 38(22-23):2880-2885. PubMed ID: 28727158
[TBL] [Abstract][Full Text] [Related]
11. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
[TBL] [Abstract][Full Text] [Related]
12. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
Romberg V; Hoefferer L; El Menyawi I
Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
[TBL] [Abstract][Full Text] [Related]
13. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
[TBL] [Abstract][Full Text] [Related]
14. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
15. Investigations of prion and virus safety of a new liquid IVIG product.
Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
[TBL] [Abstract][Full Text] [Related]
16. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
17. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
[TBL] [Abstract][Full Text] [Related]
18. Development of a Premium Quality Plasma-derived IVIg (IQYMUNE
Paolantonacci P; Appourchaux P; Claudel B; Ollivier M; Dennett R; Siret L
PDA J Pharm Sci Technol; 2018; 72(2):176-187. PubMed ID: 29158287
[TBL] [Abstract][Full Text] [Related]
19. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
Emmi L; Chiarini F
Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with the viral safety of immunoglobulins.
Hellstern P
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
